Federated Hermes Inc. Has $81.67 Million Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Federated Hermes Inc. grew its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 54.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 242,094 shares of the medical equipment provider’s stock after buying an additional 85,843 shares during the quarter. Federated Hermes Inc. owned 0.07% of Intuitive Surgical worth $81,673,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Livforsakringsbolaget Skandia Omsesidigt increased its position in Intuitive Surgical by 74.6% during the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 840 shares of the medical equipment provider’s stock worth $283,000 after purchasing an additional 359 shares in the last quarter. GraniteShares Advisors LLC acquired a new position in Intuitive Surgical during the 4th quarter worth approximately $1,210,000. Everence Capital Management Inc. increased its position in Intuitive Surgical by 2.3% during the 4th quarter. Everence Capital Management Inc. now owns 9,930 shares of the medical equipment provider’s stock worth $3,350,000 after purchasing an additional 220 shares in the last quarter. Main Street Research LLC increased its position in Intuitive Surgical by 96.6% during the 4th quarter. Main Street Research LLC now owns 73,132 shares of the medical equipment provider’s stock worth $24,672,000 after purchasing an additional 35,935 shares in the last quarter. Finally, Guerra Pan Advisors LLC increased its position in Intuitive Surgical by 10.7% during the 4th quarter. Guerra Pan Advisors LLC now owns 897 shares of the medical equipment provider’s stock worth $303,000 after purchasing an additional 87 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently issued reports on ISRG. Raymond James upped their price objective on shares of Intuitive Surgical from $372.00 to $435.00 and gave the stock an “outperform” rating in a research report on Thursday, January 25th. Barclays upped their price target on shares of Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. Mizuho upped their price target on shares of Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a research report on Thursday, January 25th. Stifel Nicolaus upped their price target on shares of Intuitive Surgical from $420.00 to $430.00 and gave the company a “buy” rating in a research report on Monday, April 8th. Finally, Citigroup upped their price target on shares of Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Six research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat, Intuitive Surgical presently has an average rating of “Moderate Buy” and an average target price of $378.48.

Intuitive Surgical Trading Down 0.4 %

ISRG opened at $372.63 on Friday. The company’s fifty day moving average price is $387.27 and its two-hundred day moving average price is $342.60. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $403.76. The company has a market cap of $132.08 billion, a price-to-earnings ratio of 74.08, a PEG ratio of 5.81 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last released its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. Intuitive Surgical had a net margin of 25.24% and a return on equity of 13.11%. The firm had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.87 billion. During the same quarter in the prior year, the company posted $1.00 earnings per share. The business’s revenue was up 11.5% on a year-over-year basis. As a group, equities analysts forecast that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares in the company, valued at $10,349,795.16. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, CEO Gary S. Guthart sold 24,325 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $376.06, for a total value of $9,147,659.50. Following the completion of the sale, the chief executive officer now owns 9,425 shares in the company, valued at $3,544,365.50. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Marshall Mohr sold 108,790 shares of the stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total transaction of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 248,418 shares of company stock worth $95,927,097. Insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.